Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $125.00 by Analysts at JMP Securities
The Cerbat Gem - 2024-05-03T23:30:42.000Z

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective raised by JMP Securities from $114.00 to $125.00 in a report issued on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 16.62% from the company’s previous close. […] Read this story